P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study

T. Westers; C. Alhan; M. van der Vorst; M. Chamuleau; C. Eeltink; G. Ossenkoppele; A. van de Loosdrecht

doi:https://doi.org/10.1016/S0145-2126(09)70123-7

P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study

T. Westers, C. Alhan, M. van der Vorst, M. Chamuleau, C. Eeltink, G. Ossenkoppele, A. van de Loosdrecht

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Journal	Leukemia research
Volume	33
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1016/S0145-2126(09)70123-7
Publication status	Published - 2009

Access to Document

https://doi.org/10.1016/S0145-2126(09)70123-7

Cite this

Westers, T., Alhan, C., van der Vorst, M., Chamuleau, M., Eeltink, C., Ossenkoppele, G., & van de Loosdrecht, A. (2009). P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study. Leukemia research, 33(SUPPL. 1). https://doi.org/10.1016/S0145-2126(09)70123-7

@article{ff71a5df7efe47bf8567cf12c7ac49eb,

title = "P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study",

author = "T. Westers and C. Alhan and {van der Vorst}, M. and M. Chamuleau and C. Eeltink and G. Ossenkoppele and {van de Loosdrecht}, A.",

year = "2009",

doi = "https://doi.org/10.1016/S0145-2126(09)70123-7",

language = "English",

volume = "33",

journal = "Leukemia research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "SUPPL. 1",

}

Westers, T , Alhan, C , van der Vorst, M , Chamuleau, M , Eeltink, C , Ossenkoppele, G & van de Loosdrecht, A 2009, 'P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study', Leukemia research, vol. 33, no. SUPPL. 1. https://doi.org/10.1016/S0145-2126(09)70123-7

TY - JOUR

T1 - P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study

AU - Westers, T.

AU - Alhan, C.

AU - van der Vorst, M.

AU - Chamuleau, M.

AU - Eeltink, C.

AU - Ossenkoppele, G.

AU - van de Loosdrecht, A.

PY - 2009

Y1 - 2009

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=65349101197&origin=inward

U2 - https://doi.org/10.1016/S0145-2126(09)70123-7

DO - https://doi.org/10.1016/S0145-2126(09)70123-7

M3 - Article

SN - 0145-2126

VL - 33

JO - Leukemia research

JF - Leukemia research

IS - SUPPL. 1

ER -

P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study

Access to Document

Other files and links

Cite this